Rosetta Genomics Ltd. engages in the provision of therapeutic, diagnostic product development, and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing a diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.
Rosetta Genomics Ltd 주요 수익원은 Banking and Financial Services이며, 최신 수익 발표에서 수익은 58,890,000입니다. 지역별로는 United States이 Rosetta Genomics Ltd의 주요 시장이며, 수익은 58,890,000입니다.
Rosetta Genomics Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 Rosetta Genomics Ltd의 순손실은 $-16입니다.